Physician profile
Vladimir Zagrebelsky
NPI 1346287000
$6,257.01
in general payments reported to CMS, 2019-2025
21 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,700 · 2020: $819 · 2021: $1,032 · 2022: $336 · 2023: $745 · 2024: $250 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $998.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $851.21 | 2019-2023 | Xarelto |
| Abbvie INC. | $697.76 | 2019-2021 | |
| Novo Nordisk INC | $679.41 | 2019-2021 | |
| Lilly USA, LLC | $424.86 | 2019-2025 | Kisunla |
| E.R. Squibb & Sons, L.L.C. | $419.19 | 2019-2024 | Camzyos |
| Aimmune Therapeutics, INC. | $249.98 | 2024-2025 | Zenpep |
| Amgen INC. | $249.74 | 2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $249.23 | 2019 | |
| Glaxosmithkline, LLC. | $201.75 | 2019 | |
| Boston Scientific Corporation | $129.26 | 2019 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $124.99 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $124.62 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $116.60 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Esperion Therapeutics, INC. | $113.64 | 2022 | |
| Avanir Pharmaceuticals, INC. | $102.69 | 2019 | |
| Ethicon US, LLC | $97.37 | 2022 | |
| Daiichi Sankyo INC. | $94.83 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Zagrebelsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.